Persisting molecular remission ten years after donor lymphocyte infusion for hematologic relapse in chronic myeloid leukemia

Haematologica

Volumn 86, Issue 5, 2001, Pages 545-546

  Mattei, Daniele ^a   Saglio, Giuseppe ^b   Gottardi, Enrico ^b   Gallamini, Andrea ^a   Mordini, Nicola ^a   Bacigalupo, Andrea ^c  

^a S CROCE E CARLE HOSPITAL   (Italy)

^b SAN LUIGI GONZAGA HOSPITAL   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

CML; DLI

Indexed keywords

ADULT; ALLOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DISEASE FREE SURVIVAL; FEMALE; HISTOCOMPATIBILITY; HUMAN; LETTER; LYMPHOCYTE TRANSFUSION; METHODOLOGY; RECURRENT DISEASE; REMISSION;

ADULT; BONE MARROW TRANSPLANTATION; DISEASE-FREE SURVIVAL; FEMALE; HISTOCOMPATIBILITY; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LYMPHOCYTE TRANSFUSION; RECURRENCE; REMISSION INDUCTION; TRANSPLANTATION, HOMOLOGOUS;

EID: 0035346023     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Roman J, Alvarez MA, Torres A. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation. Haematologica 2000; 85:1072-82.
2. Bordignon C, Carlo-Stella C, Colombo MP, et al. Cell therapy: achievements and perspectives. Haematologica 1999; 84:1110-49.
3. Dazzi F, Szydlo RM, Goldman JM. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: where we now stand. Exp Hematol 1999; 27:1477-86.
4. Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86:1261-8.
5. van Rhee F, Lin F, Cullis JO, et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994; 83: 3377-83.
6. Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15:433-44.
7. Dazzi F, Szydlo RM, Cross NC, et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2000; 96:2712-6.
8. Martinelli G, Montefusco V, Testoni N, et al. Clinical value of quantitative long-term assessment of bcr-abl chimeric transcript in chronic myelogenous leukemia patients after allogeneic bone marrow transplantation. Haematologica 2000; 85:653-8.
9. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86:2041-50.
10. + chronic myelogenous leukemia at first relapse after allogeneic stem cell transplant: an EBMT retrospective analysis.The Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2000; 95:3328-34.